Servier, IDEAYA Partner to Globalize Uveal Melanoma Therapy

Servier, an independent global pharmaceutical organization governed by a foundation, along with IDEAYA Biosciences, Inc., a prominent precision medicine oncology firm, have declared an exclusive licensing agreement aimed at making darovasertib, a promising therapy for a rare form of eye cancer, accessible to patients around the globe. As part of this agreement, Servier acquires the regulatory and commercial rights for darovasertib in all regions outside the United States.

IDEAYA will maintain its rights for darovasertib within the United States. Darovasertib, a powerful and selective protein kinase C (PKC) inhibitor, is being developed to effectively target both primary and metastatic uveal melanoma (UM).

“At Servier, our mission is to deliver transformative therapies to patients with significant needs. Our collaboration with IDEAYA is a significant step to make darovasertib the potential first-in-class treatment available to uveal melanoma patients worldwide.

Also Read: Maxivision Launches 10 Super Speciality Eye Centres in Chennai

Today, there are limited treatment options and there is an urgent need to improve patient outcomes. We look forward to leveraging our global oncology network, and expertise in developing oncology targeted therapies, to make this groundbreaking treatment accessible to patients across the globe.”

Arnaud Lallouette, executive vice-president global medical & patient affairs at Servier, said: “Darovasertib addresses a significant unmet need, and we are thrilled to partner with Servier to globally develop it as a potential standard-of-care for uveal melanoma patients worldwide.

This partnership enables IDEAYA and Servier to accelerate the global development for darovasertib across three phase 3 registrational trials, aiming to improve patient outcomes in the neoadjuvant, adjuvant and metastatic settings.”